Patent estate

BioMarin Pharmaceutical Inc. — Patent Portfolio

4 drugs with active patents · 0 active patents · 0 expired · 4 biologics with BPCIA exclusivity

AI-enriched 0/0 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

Loss of exclusivity calendar · next 12 years

Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.

1 2026 1 2029

Patent estate by drug

Aldurazyme (LARONIDASE)

🧬 BPCIA biologic exclusivity to 2015-04-30

Aryplase (GALSULFASE)

🧬 BPCIA biologic exclusivity to 2017-05-31

Rhgalns (ELOSULFASE ALFA)

🧬 BPCIA biologic exclusivity to 2026-02-14

Rhttp1 (CERLIPONASE ALFA)

🧬 BPCIA biologic exclusivity to 2029-04-27

Sources

FDA Orange Book — small-molecule patents listed against approved NDAs.
FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
USPTO Patent Public Search — title, abstract, claim text grounding.
AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track BioMarin Pharmaceutical Inc.'s patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export